Literature DB >> 29730641

PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer.

Jessica Bate1, Stephen Baker2, Judith Breuer3, Julia C Chisholm4, Juliet Gray1,5, Sophie Hambleton6,7, Aimee Houlton2, Mark Jit8,9, Stephen Lowis10, Guy Makin11, Catherine O'Sullivan12, Soonie R Patel13, Robert Phillips14, Neil Ransinghe15, Mary Elizabeth Ramsay16, Roderick Skinner17, Keith Wheatley2, Paul T Heath12.   

Abstract

OBJECTIVE: To determine the likely rate of patient randomisation and to facilitate sample size calculation for a full-scale phase III trial of varicella zoster immunoglobulin (VZIG) and aciclovir as postexposure prophylaxis against chickenpox in children with cancer.
DESIGN: Multicentre pilot randomised controlled trial of VZIG and oral aciclovir.
SETTING: England, UK. PATIENTS: Children under 16 years of age with a diagnosis of cancer: currently or within 6 months of receiving cancer treatment and with negative varicella zoster virus (VZV) serostatus at diagnosis or within the last 3 months.
INTERVENTIONS: Study participants who have a significant VZV exposure were randomised to receive PEP in the form of VZIG or aciclovir after the exposure. MAIN OUTCOME MEASURES: Number of patients registered and randomised within 12 months of the trial opening to recruitment and incidence of breakthrough varicella.
RESULTS: The study opened in six sites over a 13-month period. 482 patients were screened for eligibility, 32 patients were registered and 3 patients were randomised following VZV exposure. All three were randomised to receive aciclovir and there were no cases of breakthrough varicella.
CONCLUSIONS: Given the limited recruitment to the PEPtalk2 pilot, it is unlikely that the necessary sample size would be achievable using this strategy in a full-scale trial. The study identified factors that could be used to modify the design of a definitive trial but other options for defining the best means to protect such children against VZV should be explored. TRIAL REGISTRATION NUMBER: ISRCTN48257441, EudraCT number: 2013-001332-22, sponsor: University of Birmingham. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  paediatric haematology; paediatric oncology; prophylaxis; varicella

Mesh:

Substances:

Year:  2018        PMID: 29730641     DOI: 10.1136/archdischild-2017-314212

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  PAnTher Cub: procalcitonin-guided antibiotic therapy for febrile neutropenia in children and young people with cancer - a single-arm pilot study.

Authors:  Jessica Elizabeth Morgan; Bob Phillips
Journal:  BMJ Paediatr Open       Date:  2022-03

2.  Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.

Authors:  Myron J Levin; Jennifer M Duchon; Geeta K Swamy; Anne A Gershon
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

Review 3.  Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children.

Authors:  Jessica E Morgan; Bob Phillips; Gabrielle M Haeusler; Julia C Chisholm
Journal:  Infect Drug Resist       Date:  2021-03-30       Impact factor: 4.003

4.  Post-exposure prophylaxis to prevent varicella in immunocompromised children.

Authors:  Makoto Yamaguchi; Nobuyuki Tetsuka; Toshihiko Okumura; Kazunori Haruta; Takako Suzuki; Yuka Torii; Jun-Ichi Kawada; Yoshinori Ito
Journal:  Infect Prev Pract       Date:  2022-08-28

5. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.